Synairgen Plc – Strategy, SWOT and Corporate Finance Report
- Pages: 49
- Published: October 2019
- Report Code: MLPH82160FSA
Synairgen Plc – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company
Key Highlights
Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) for chronic obstructive pulmonary disease (COPD) in Phase II trial; The company develops drugs based on BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.
Scope
Detailed information on Synairgen Plc required for business and competitor intelligence needs
A study of the major internal and external factors affecting Synairgen Plc in the form of a SWOT analysis
An in-depth view of the business model of Synairgen Plc including a breakdown and examination of key business segments
News about Synairgen Plc, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Synairgen Plc and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Synairgen Plc as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Synairgen Plcs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Verona Pharma Plc
Theravance Biopharma Inc
Oxagen Ltd
Novartis AG
Napp Pharmaceuticals Ltd
GlaxoSmithKline Plc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple report purchases.